FCGR3A and breast cancer: As these promising pre-clinical results suggested potential clinical interest in extending the proportion of treatable HER2 breast cancers, one important issue to look at was the absence of influence of the FcγRIIIA-158 F/V polymorphism in the case of tumors overexpressing only weakly HER2.